HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kmart restructuring

This article was originally published in The Rose Sheet

Executive Summary

Gregg Treadway appointed exec VP, store operations to head new field organizational structure, effective immediately, retailer announces Feb. 5. Formerly senior VP-Midwest division, Treadway will report to CEO Chuck Conaway. New structure includes five separate operating divisions - four geographical regions and one Super Center division rather than six geographical field locations. Newly appointed division presidents report to Treadway. Paul Hueber to International Division; Michael Jardina to Super Centers Division; Douglas Meissner to Northeast Division; Lee Viliborghi to West Division; and William Wulfers to Southeast Division. Move marks first step towards reorganization after retailer filed for Chapter 11 Jan. 22 (1"The Rose Sheet" Jan. 28, 2002, p. 7)...

You may also be interested in...



Kmart Reorganization Effort Backed With $2 Bil. Loan

Kmart will finance a "fast-track" reorganization effort under Chapter 11 bankruptcy protection with a $2 bil. financing facility, the Troy, Mich. retailer announced Jan. 22

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel